Summit Therapeutics to Participate in SunTrust Robinson Humphrey’s 2016 Orphan Drug Day
February 17, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
January 21, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, UK, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’)...
FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular Dystrophy
January 06, 2016 17:46 ET
|
FibroGen, Inc.
SAN FRANCISCO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”) announced today enrollment of the first two patients in an open-label, multicenter Phase 2 clinical...
Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational Progress
December 17, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Presents Additional Data From Phase 1b Modified Diet Clinical Trial of SMT C1100 in DMD Patients at WMS
September 30, 2015 07:00 ET
|
Summit Therapeutics plc
10 of 12 Patients Achieved Plasma Concentrations Expected to Increase Utrophin Levels by Approximately 30% or Greater
Phase 2 Proof of Concept Trial Design Outlined, Expected to Initiate Q4...
Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2015 and Operational Progress
August 27, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics to Report Second Quarter 2015 Financial Results on 27 August 2015
August 24, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 24, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective in Duchenne Muscular Dystrophy
August 17, 2015 07:00 ET
|
Summit Therapeutics plc
Primary Objective Met; Plasma Absorption of SMT C1100 Observed at a Level Suitable for Further Development
SMT C1100 to Progress into Phase 2 Open-label Trial
Conference Call Scheduled...
Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015
June 11, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, June 11, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
September 08, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...